Remove clinical zoster
article thumbnail

L and J-HZ by L&J Bio for Herpes Zoster (Shingles): Likelihood of Approval

Pharmaceutical Technology

L and J-HZ is under clinical development by L&J Bio and currently in Phase I for Herpes Zoster (Shingles).

40
article thumbnail

Shingles vaccine offers a decade of protection in older adults

European Pharmaceutical Review

GSK announced Shingrix (Zoster Vaccine Recombinant, Adjuvanted), the first approved shingles vaccine to combine a non-live antigen with a GSK-made adjuvant, can prevent shingles (herpes zoster) for at least decade. Shingles occurs when the varicella zoster virus (VZV) is reactivated in a patient.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

VTP-400 by Barinthus Biotherapeutics for Herpes Zoster (Shingles): Likelihood of Approval

Pharmaceutical Technology

VTP-400 is under clinical development by Barinthus Biotherapeutics and currently in Phase I for Herpes Zoster (Shingles).

40
article thumbnail

Shingles Vaccines Against Dementia & Flu Shots vs. Heart Attacks

The People's Pharmacy

During seven years of follow-up, people who had received the herpes zoster vaccine were 20 percent less likely to develop dementia. They go on to add: “Our rigorous causal approach allows for the conclusion that herpes zoster vaccination is very likely an effective means of preventing or delaying the onset of dementia.

article thumbnail

Herpes zoster infection increases risk of stroke and coronary heart disease

Hospital Pharmacy Europe

Infection with herpes zoster appears associated with a longer term higher risk of developing both a stroke and coronary heart disease. Herpes zoster infection and cardiovascular events. Herpes Zoster and Long-Term Risk of Cardiovascular Disease. Citation Curhan SG et al. J Am Heart Assoc.

article thumbnail

Japan’s MHLW accepts GSK’s submission for shingles vaccine in adults

Pharmaceutical Technology

The Japanese Ministry of Health, Labour and Welfare (MHLW) has accepted GlaxoSmithKline’s (GSK) regulatory application for recombinant, adjuvanted Zoster vaccine, Shingrix, for preventing shingles (herpes zoster) in at-risk adults of the age 18 years and above.

article thumbnail

Look out GSK, Pfizer and BioNTech are coming for Shingrix

pharmaphorum

Having already brought their mRNA-based CVID-19 vaccine Comirnaty to market at breakneck speed, Pfizer and BioNTech are hoping to fast-track a vaccine for shingles based on the same technology platform through clinical development, with trials due to start later this year.

Vaccines 104